The house dust mite allergy market is segmented product type into tablets, nasal drops and injectable. The tablets market was the largest segment of the house dust mite allergy market segmented by product type, accounting for 75.76% or $1.6 billion of the total in 2024. Going forward, the nasal drops segment is expected to be the fastest growing segment in the house dust mite allergy market segmented by product type, at a CAGR of 16.06% during 2024-2029.
The house dust mite allergy market is segmented by treatment type into medication, nasal irrigation and other types. The medication market was the largest segment of the house dust mite allergy market segmented by treatment type, accounting for 74.34% or $1.57 billion of the total in 2024. Going forward, the nasal irrigation segment is expected to be the fastest growing segment in the house dust mite allergy market segmented by treatment type, at a CAGR of 16.79% during 2024-2029.
The house dust mite allergy market is segmented by diagnosis into skin prick test (SPT), specific immunoglobulin E (IgE) and blood test and other diagnostic. The skin prick test (SPT) market was the largest segment of the house dust mite allergy market segmented by diagnosis, accounting for 60.17% or $1.27 billion of the total in 2024. Going forward, the specific immunoglobulin E (IgE) segment is expected to be the fastest growing segment in the house dust mite allergy market segmented by diagnosis, at a CAGR of 15.67% during 2024-2029.
The house dust mite allergy market is segmented by dosage forms into solid and liquid. The solid market was the largest segment of the house dust mite allergy market segmented by dosage forms, accounting for 75.76% or $1.6 billion of the total in 2024. Going forward, the liquid segment is expected to be the fastest growing segment in the house dust mite allergy market segmented by dosage forms, at a CAGR of 14.23% during 2024-2029.
The house dust mite allergy market is segmented by end users into hospitals, homecare, specialty clinics and other end users. The homecare market was the largest segment of the house dust mite allergy market segmented by end users, accounting for 64.37% or $1.36 billion of the total in 2024. Going forward, the homecare segment is expected to be the fastest growing segment in the house dust mite allergy market segmented by end users, at a CAGR of 14.74% during 2024-2029.
North America was the largest region in the house dust mite allergy market, accounting for 36.32% or $767.33 million of the total in 2024. It was followed by Asia-Pacific, Western Europe and then the other regions. Going forward, the fastest-growing regions in the house dust mite allergy market will be Asia-Pacific and South America where growth will be at CAGRs of 16.30% and 15.80% respectively. These will be followed by Eastern Europe and North America where the markets are expected to grow at CAGRs of 14.52% and 12.92% respectively.
The global house dust mite allergy markets are concentrated, with large players operating in the market. The top 10 competitors in the market made up 46.17% of the total market in 2023. Sanofi SA was the largest competitor with a 8.30% share of the market, followed by Teva Pharmaceutical Industries Ltd. with 7.67%, Johnson and Johnson Services Inc., with 6.63%, Merck & Co. Inc. with 6.48%, Bayer AG with 6.35%, ALK-Abelló A/S with 3.55%, Shionogi & Co. Ltd. with 2.52%, CSL Limited. with 1.72%, GlaxoSmithKline Plc. with 1.63% and Merz Pharma GmbH & Co KGaA with 1.32%.
This report describes and explains the house dust mite allergy market and covers 2019-2024, termed the historic period, and 2024-2029, 2034F termed the forecast period. The report evaluates the market across each region and for the major economies within each region.
The global house dust mite allergy market reached a value of nearly $2.11 billion in 2024, having grown at a compound annual growth rate (CAGR) of 9.31% since 2019. The market is expected to grow from $2.11 billion in 2024 to $4.1 billion in 2029 at a rate of 14.19%. The market is then expected to grow at a CAGR of 14.06% from 2029 and reach $7.91 billion in 2034.
Growth in the historic period resulted from rising healthcare expenditures, increased pet ownership, rising asthma prevalence and growing demand for prescription-based drugs. Factors that negatively affected growth in the historic period were the discontinuation of drug trials and high cost of allergen immunotherapy.
Going forward, rising air pollution levels, increasing prevalence of allergic diseases, changing climate patterns and favorable government initiatives will drive growth. Factor that could hinder the growth of the house dust mite allergy market in the future include were regulatory compliance and delays and adverse effects of treatments.
The top opportunities in the house dust mite allergy market segmented by product type will arise in the tablets segment, which will gain $1.5 billion of global annual sales by 2029. The top opportunities in the house dust mite allergy market segmented by treatment type will arise in the medication segment, which will gain $1.45 billion of global annual sales by 2029. The top opportunities in the house dust mite allergy market segmented by diagnosis will arise in the skin prick test (SPT) segment, which will gain $1.14 billion of global annual sales by 2029. The top opportunities in the house dust mite allergy market segmented by dosage forms will arise in the solid segment, which will gain $1.5 billion of global annual sales by 2029. The top opportunities in the house dust mite allergy market segmented by end users will arise in the homecare segment, which will gain $1.34 billion of global annual sales by 2029 The house dust mite allergy market size will gain the most in the USA at $596.3 million.
Market-trend-based strategies for the house dust mite allergy market include breakthrough in allergy care for children and adolescents, strategic partnerships driving the evolution of immunotherapy in allergy care, advances in precision immunotherapy for house dust mite allergy and asthma, innovative AI-powered allergy testing revolutionizes market dynamics and regulatory approvals for advanced immunotherapy tablets.
Player-adopted strategies in the house dust mite allergy market include focus on expanding its business capabilities through strategic partnerships.
To take advantage of the opportunities, the analyst recommends the house dust mite allergy companies to focus on expanding age-specific therapies to improve access and adherence, focus on developing targeted therapies to modulate immune responses, focus on advancing allergy testing with AI and precision diagnostics, focus on expanding regulatory approvals for immunotherapy tablets, focus on expanding tablet offerings for house dust mite allergy, focus on expanding medication offerings for house dust mite allergy, focus on enhancing diagnostic offerings for house dust mite allergy, focus on solid dosage forms to drive market growth, expand in emerging markets, focus on expanding strategic partnerships to enhance distribution channels, focus on competitive and value-based pricing, focus on targeted digital campaigns, focus on educating and engaging consumers and focus on expanding in the homecare market.
This product will be delivered within 3-5 business days.
The house dust mite allergy market is segmented by treatment type into medication, nasal irrigation and other types. The medication market was the largest segment of the house dust mite allergy market segmented by treatment type, accounting for 74.34% or $1.57 billion of the total in 2024. Going forward, the nasal irrigation segment is expected to be the fastest growing segment in the house dust mite allergy market segmented by treatment type, at a CAGR of 16.79% during 2024-2029.
The house dust mite allergy market is segmented by diagnosis into skin prick test (SPT), specific immunoglobulin E (IgE) and blood test and other diagnostic. The skin prick test (SPT) market was the largest segment of the house dust mite allergy market segmented by diagnosis, accounting for 60.17% or $1.27 billion of the total in 2024. Going forward, the specific immunoglobulin E (IgE) segment is expected to be the fastest growing segment in the house dust mite allergy market segmented by diagnosis, at a CAGR of 15.67% during 2024-2029.
The house dust mite allergy market is segmented by dosage forms into solid and liquid. The solid market was the largest segment of the house dust mite allergy market segmented by dosage forms, accounting for 75.76% or $1.6 billion of the total in 2024. Going forward, the liquid segment is expected to be the fastest growing segment in the house dust mite allergy market segmented by dosage forms, at a CAGR of 14.23% during 2024-2029.
The house dust mite allergy market is segmented by end users into hospitals, homecare, specialty clinics and other end users. The homecare market was the largest segment of the house dust mite allergy market segmented by end users, accounting for 64.37% or $1.36 billion of the total in 2024. Going forward, the homecare segment is expected to be the fastest growing segment in the house dust mite allergy market segmented by end users, at a CAGR of 14.74% during 2024-2029.
North America was the largest region in the house dust mite allergy market, accounting for 36.32% or $767.33 million of the total in 2024. It was followed by Asia-Pacific, Western Europe and then the other regions. Going forward, the fastest-growing regions in the house dust mite allergy market will be Asia-Pacific and South America where growth will be at CAGRs of 16.30% and 15.80% respectively. These will be followed by Eastern Europe and North America where the markets are expected to grow at CAGRs of 14.52% and 12.92% respectively.
The global house dust mite allergy markets are concentrated, with large players operating in the market. The top 10 competitors in the market made up 46.17% of the total market in 2023. Sanofi SA was the largest competitor with a 8.30% share of the market, followed by Teva Pharmaceutical Industries Ltd. with 7.67%, Johnson and Johnson Services Inc., with 6.63%, Merck & Co. Inc. with 6.48%, Bayer AG with 6.35%, ALK-Abelló A/S with 3.55%, Shionogi & Co. Ltd. with 2.52%, CSL Limited. with 1.72%, GlaxoSmithKline Plc. with 1.63% and Merz Pharma GmbH & Co KGaA with 1.32%.
This report describes and explains the house dust mite allergy market and covers 2019-2024, termed the historic period, and 2024-2029, 2034F termed the forecast period. The report evaluates the market across each region and for the major economies within each region.
The global house dust mite allergy market reached a value of nearly $2.11 billion in 2024, having grown at a compound annual growth rate (CAGR) of 9.31% since 2019. The market is expected to grow from $2.11 billion in 2024 to $4.1 billion in 2029 at a rate of 14.19%. The market is then expected to grow at a CAGR of 14.06% from 2029 and reach $7.91 billion in 2034.
Growth in the historic period resulted from rising healthcare expenditures, increased pet ownership, rising asthma prevalence and growing demand for prescription-based drugs. Factors that negatively affected growth in the historic period were the discontinuation of drug trials and high cost of allergen immunotherapy.
Going forward, rising air pollution levels, increasing prevalence of allergic diseases, changing climate patterns and favorable government initiatives will drive growth. Factor that could hinder the growth of the house dust mite allergy market in the future include were regulatory compliance and delays and adverse effects of treatments.
The top opportunities in the house dust mite allergy market segmented by product type will arise in the tablets segment, which will gain $1.5 billion of global annual sales by 2029. The top opportunities in the house dust mite allergy market segmented by treatment type will arise in the medication segment, which will gain $1.45 billion of global annual sales by 2029. The top opportunities in the house dust mite allergy market segmented by diagnosis will arise in the skin prick test (SPT) segment, which will gain $1.14 billion of global annual sales by 2029. The top opportunities in the house dust mite allergy market segmented by dosage forms will arise in the solid segment, which will gain $1.5 billion of global annual sales by 2029. The top opportunities in the house dust mite allergy market segmented by end users will arise in the homecare segment, which will gain $1.34 billion of global annual sales by 2029 The house dust mite allergy market size will gain the most in the USA at $596.3 million.
Market-trend-based strategies for the house dust mite allergy market include breakthrough in allergy care for children and adolescents, strategic partnerships driving the evolution of immunotherapy in allergy care, advances in precision immunotherapy for house dust mite allergy and asthma, innovative AI-powered allergy testing revolutionizes market dynamics and regulatory approvals for advanced immunotherapy tablets.
Player-adopted strategies in the house dust mite allergy market include focus on expanding its business capabilities through strategic partnerships.
To take advantage of the opportunities, the analyst recommends the house dust mite allergy companies to focus on expanding age-specific therapies to improve access and adherence, focus on developing targeted therapies to modulate immune responses, focus on advancing allergy testing with AI and precision diagnostics, focus on expanding regulatory approvals for immunotherapy tablets, focus on expanding tablet offerings for house dust mite allergy, focus on expanding medication offerings for house dust mite allergy, focus on enhancing diagnostic offerings for house dust mite allergy, focus on solid dosage forms to drive market growth, expand in emerging markets, focus on expanding strategic partnerships to enhance distribution channels, focus on competitive and value-based pricing, focus on targeted digital campaigns, focus on educating and engaging consumers and focus on expanding in the homecare market.
This product will be delivered within 3-5 business days.
Table of Contents
1 Executive Summary
6 Market Characteristics
7 Major Market Trends
8 Global House Dust Mite Allergy Growth Analysis And Strategic Analysis Framework
9 Global House Dust Mite Allergy Market Segmentation
10 House Dust Mite Allergy Market, Regional and Country Analysis
11 Asia-Pacific Market
12 Western Europe Market
13 Eastern Europe Market
14 North America Market
15 South America Market
16 Middle East Market
17 Africa Market
18 Competitive Landscape And Company Profiles
19 Other Major And Innovative Companies
22 Key Mergers And Acquisitions
23 Recent Developments In The House Dust Mite Allergy Market
24 Opportunities And Strategies
25 House Dust Mite Allergy Market, Conclusions And Recommendations
26 Appendix
Executive Summary
House Dust Mite Allergy Global Market Opportunities And Strategies To 2034 provides the strategists; marketers and senior management with the critical information they need to assess the global house dust mite allergy market as it emerges from the COVID-19 shut down.Reasons to Purchase:
- Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
- Understand how the market is being affected by the coronavirus and how it is likely to emerge and grow as the impact of the virus abates.
- Create regional and country strategies on the basis of local data and analysis.
- Identify growth segments for investment.
- Outperform competitors using forecast data and the drivers and trends shaping the market.
- Understand customers based on the latest market research findings.
- Benchmark performance against key competitors.
- Utilize the relationships between key data sets for superior strategizing.
- Suitable for supporting your internal and external presentations with reliable high-quality data and analysis.
Description
Where is the largest and fastest-growing market for house dust mite allergy? how does the market relate to the overall economy; demography and other similar markets? What forces will shape the market going forward? The house dust mite allergy market global report answers all these questions and many more.The report covers market characteristics; size and growth; segmentation; regional and country breakdowns; competitive landscape; market shares; trends and strategies for this market. It traces the market’s history and forecasts market growth by geography. It places the market within the context of the wider house dust mite allergy market; and compares it with other markets.
The report covers the following chapters
- Introduction And Market Characteristics- Brief introduction to the segmentations covered in the market, definitions and explanations about the segment by product type, by treatment type, by diagnosis, by dosage forms and by end users.
- Key Trends- Highlights the major trends shaping the global market. This section also highlights likely future developments in the market.
- Growth Analysis And Strategic Analysis Framework- Analysis on PESTEL, end use industries, market growth rate, global historic (2019-2024) and forecast (2024-2029, 2034F) market values and drivers and restraints that support and control the growth of the market in the historic and forecast periods, forecast growth contributors and total addressable market (TAM).
- Global Market Size And Growth- Global historic (2019-2024) and forecast (2024-2029, 2034F) market values and drivers and restraints that support and control the growth of the market in the historic and forecast periods.
- Regional And Country Analysis- Historic (2019-2024) and forecast (2024-2029, 2034F) market values and growth and market share comparison by region and country.
- Market Segmentation- Contains the market values (2019-2024) (2024-2029, 2034F) and analysis for each segment by product type, by treatment type, by diagnosis, by dosage forms and by end users in the market.Historic (2019-2024) and forecast (2024-2029) and (2029-2034) market values and growth and market share comparison by region market.
- Regional Market Size And Growth- Regional market size (2024), historic (2019-2024) and forecast (2024-2029, 2034F) market values and growth and market share comparison of countries within the region. This report includes information on all the regions Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa and major countries within each region.
- Competitive Landscape- Details on the competitive landscape of the market, estimated market shares and company profiles of the leading players.
- Other Major And Innovative Companies- Details on the company profiles of other major and innovative companies in the market.
- Competitive Benchmarking- Briefs on the financials comparison between major players in the market.
- Competitive Dashboard- Briefs on competitive dashboard of major players.
- Key Mergers And Acquisitions- Information on recent mergers and acquisitions in the market covered in the report. This section gives key financial details of mergers and acquisitions, which have shaped the market in recent years.
- Recent Developments- Information on recent developments in the market covered in the report.
- Market Opportunities And Strategies- Describes market opportunities and strategies based on findings of the research, with information on growth opportunities across countries, segments and strategies to be followed in those markets.
- Conclusions And Recommendations- This section includes recommendations for house dust mite allergy providers in terms of product/service offerings geographic expansion, marketing strategies and target groups.
- Appendix- This section includes details on the NAICS codes covered, abbreviations and currencies codes used in this report.
Markets Covered:
1) By Product Type: Tablets; Nasal Drops; Injectable2) By Treatment Type: Medication; Nasal Irrigation; Other Types
3) By Diagnosis: Skin Prick Test (SPT); Specific Immunoglobulin E (IgE) And Blood Test; Other Diagnostics
4) By Dosage Forms: Solid; Liquid
5) By End Users: Hospitals; Homecare; Specialty Clinics; Other End Users
Key Companies Profiled: Sanofi SA; Teva Pharmaceutical Industries Ltd.; Johnson and Johnson Services Inc.; Merck & Co. Inc.; Bayer AG
Countries: China; Australia; India; Indonesia; Japan; South Korea; USA; Canada; Brazil; France; Germany; UK; Italy; Spain; Russia
Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
Time Series: Five years historic and ten years forecast.
Data: Ratios of market size and growth to related markets; GDP proportions; expenditure per capita; house dust mite allergy indicators comparison.
Data segmentations:country and regional historic and forecast data; market share of competitors; market segments.
Sourcing and Referencing:Data and analysis throughout the report is sourced using end notes.
Companies Mentioned
- Sanofi SA
- Teva Pharmaceutical Industries Ltd.
- Johnson and Johnson Services Inc.
- Merck & Co. Inc.
- Bayer AG
- ALK-Abelló A/S
- Shionogi & Co. Ltd.
- CSL Limited
- GlaxoSmithKline Plc
- Merz Pharma GmbH & Co KGaA
- Torii Pharmaceutical Co., Ltd.
- Daiichi Sankyo Company Limited
- Eisai Co., Ltd.
- Astellas Pharma Inc.
- Kowa Company, Ltd.
- Boryung Biopharma Co., Ltd.
- SK Chemicals
- Trio Lifescience Private Limited
- Zhejiang I-biological Technology Co. Ltd.
- Metropolis Healthcare
- Johnson Group
- Xinhualian Company
- Worg Pharmaceuticals
- T-Balance Therapeutics
- Stallergenes Greer International AG
- Ergomed PLC
- HAL Allergy Group
- Anergis Sa
- Microgen
- Immuno Ltd.
- Thermo Fisher Scientific
- Stallergenes Greer
- NPO Microgen
- Bausch & Lomb
- Johnson & Johnson
- Merck & Co. Inc.
- Novartis Corporation
- Amgen Inc
- Pfizer Inc
- Eli Lilly and Company
- Catalent Inc
- Hikma Pharmaceuticals PLC
- Adcock Ingram Holdings Limited
- Aspen Pharmacare Holdings Limited
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 331 |
| Published | June 2025 |
| Forecast Period | 2024 - 2034 |
| Estimated Market Value ( USD | $ 2.11 Billion |
| Forecasted Market Value ( USD | $ 7.91 Billion |
| Compound Annual Growth Rate | 14.1% |
| Regions Covered | Global |
| No. of Companies Mentioned | 44 |
